DouglasWBlayneyMD

Breast Cancer, Hematologic Oncology

Professor, Medicine - Oncology, Stanford University Medical Center

Dr. Blayney is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Fax+1 650-498-5840

University of California (San Diego) Medical CenterResidency, Internal Medicine, 1977 - 1980
University of California San Diego School of MedicineClass of 1977

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Fellow (FASCO) American Society of Clinical Oncologists, 2007

PubMed

2 citations
Long-Term Engagement of Patients With Advanced Cancer: Results From the EPAC Randomized Clinical Trial.
Manali I Patel, Madhuri Agrawal, Douglas W Blayney, M Kate Bundorf, Arnold Milstein
JAMA Oncology. 2024-07-01
Evidence of compensatory neural hyperactivity in a subgroup of chemotherapy-treated breast cancer survivors and its association with brain aging.
Michele M Mulholland, Alexa Stuifbergen, Alexa De La Torre Schutz, Oscar Y Franco Rocha, Douglas W Blayney
Medrxiv. 2024-04-22
Computing the Cost of Care per Patient per Day for Patients With Metastatic Neuroendocrine Neoplasms.
Divya M Gupta, James Barnes, FeiFei Qin, Kristopher Kapphahn, Kathleen Hornbacker
JCO Oncology Practice. 2024-02-01

Journal Articles

Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults with Non–Small Cell Lung Cancer
Douglas W Blayney, Santosh Nair, JAMA Oncology

Lectures

Plinabulin (Plin) combined with half-dose pegfilgrastim (Peg) compared with full-dose peg alone for chemotherapy- induced-neutropenia (CIN): Neutrophil, bone pain, and...
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Comparison of pegfilgrastim (Peg), plinabulin (Plin), and the combination for chemotherapy (Chemo) induced neutropenia (CIN) prevention: Rationale for the combination.
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (plin) + Pegfilgrastim (peg) Versus (vs) Peg Alone for Tac (docetaxel, doxorubicin, cyclophosphami...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN) Prevention, Mobilizes CD34+ Cells through a Mechanism of Action (MoA) Diff...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase (Ï†) 2 results from a...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

How Do Cancer Biosimilars Stack up Against the Original Products?February 4th, 2022
‘American Ninja Warrior’ Contestant Overcame Cancer but Still Suffers from Memory Loss; Exercise Can Reduce Chemo BrainSeptember 28th, 2021
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual MeetingJune 7th, 2021
Join now to see all